To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLC

Hunan Province Tumor Hospital130 enrolled

Overview

Evaluated the correlation between the qualitative test results of Xiamen Aide the gene test specified by the test reagent and the efficacy of relevant targeted drugs in patients with non-small cell lung cancery, and the research data is used to support the registration and marketing of the assessment reagent

Study Type

OBSERVATIONAL

Enrollment

130

Conditions

Non Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1)≥18; * 2\) advanced non-small cell lung cancer confirmed by histopathology; * 3\) Patients with NSCLC who have previously or are taking gefitinib (first-line therapy) or osimertinib (post-TKI resistance) or crizotinib monotherapy, and the response to treatment can be assessed; * 4\) Have sufficient FFPE tissue samples within 5 years: 5 large specimens/case; There were 10 puncture specimens/case Exclusion Criteria: * 1\) Combination therapy with chemotherapy/radiotherapy/other targeted drugs/immunotherapy drugs; * 2)Maintenance therapy if the disease does not progress after treatment with other antitumor methods

Locations (1)

Hunan Cancer hospital

Changsha, Hunan, China

Outcomes

Primary Outcomes

PFS

Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)

Time frame: 2 year

Secondary Outcomes

ORR

Defined as the proportion of subjects in complete remission (CR) and partial remission (PR) to the total subjects

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.